Renal and Cardiovascular Effects of Terlipressin in Patients With Cirrhosis and Ascites
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00115947|
Recruitment Status : Completed
First Posted : June 27, 2005
Last Update Posted : March 9, 2006
The purpose of this study is to investigate the effect of terlipressin on myocardial perfusion and renal function.
Hypothesis: Significant improvement of renal function reflected by: glomerular filtration rate (GFR), renal blood flow (RBF), excretion of salt and metabolites in the urine and related hormones and peptides in the blood. No effect on the systolic function of the heart.
|Condition or disease||Intervention/treatment||Phase|
|Cirrhosis Ascites||Drug: Terlipressin||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Crossover Assignment|
|Study Start Date :||December 2004|
|Study Completion Date :||January 2006|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00115947
|Copenhagen, Hvidovre, Denmark, 2650|
|Principal Investigator:||Aleksander Krag Krag, MD||Hvidovre University Hospital|